Title:
ADIPONECTIN IN LONG-TERM HEMODIALYSIS PATIENTS

MASASHI KUBO¹ ;MASASHI KUBO¹

1. Tago Kidney and Urology Clinic

E-mail address corresponding author:
kbm@h7.dion.ne.jp

Background:
Atherosclerotic complications, such as cardiovascular and cerebrovascular diseases, are the principal causes of mortality in long-term hemodialysis patients. Adiponectin is an adipocyte-specific secretory protein, which was recently discovered, and is thought to play a protective role in the atherosclerotic process in the human body. Adiponectin is reported to be related to obesity, diabetes and cardiovascular disease. The aim of this study was to assess the relationship between plasma adiponectin levels and the clinical and biochemical parameters in long-term hemodialysis patients.

Methods:
One hundred and fifty-three chronic renal failure patients, which included 110 non-diabetic patients and 43 diabetic patients, under maintenance hemodialysis treatment and 28 healthy control subjects were enrolled for this study. Fasting blood samples for analysis of the levels of adiponectin, total cholesterol, HDL cholesterol, triglyceride and glucose were obtained just before hemodialysis session.

Results:
Plasma adiponectin levels were significantly higher in chronic renal failure patients than in healthy subjects (p<0.01). Among the chronic renal failure patients, adiponectin levels were significantly higher in the non-diabetic patients than the diabetic patients (p<0.01). By stepwise multiple regression analysis, adiponectin was positively correlated with HDL cholesterol (p<0.001), age (p<0.01) and negatively correlated with BMI (p<0.01) in the non-diabetic patients.

Conclusion:
Plasma adiponectin levels were higher in chronic renal failure patients than those in healthy subjects. Our results demonstrated that adiponectin had significant and independent association with age, HDL cholesterol, and BMI in long-term hemodialysis patients.

Subject:
Complications

Back